<DOC>
	<DOCNO>NCT02727660</DOCNO>
	<brief_summary>This Phase III randomize , double-blind , parallel group , multi-center , 52-week COPD exacerbation lung function study PT009 320/9.6 μg , PT009 160/9.6 μg PT005 9.6 μg , administer BID .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety PT009 Compared PT005 COPD Exacerbations Over 52-Week Period Subjects With Moderate Very Severe COPD ( Sophos )</brief_title>
	<detailed_description>This Phase III randomize , double-blind , parallel group , multi-center , 52-week COPD exacerbation lung function study . Subjects undergo 1- 4-week Screening Period . Subjects successfully complete Screening Period randomize one follow three treatment group : PT009 320/9.6 μg , PT009 160/9.6 μg PT005 9.6 μg , administer BID . Following randomization , subject enter Treatment Period undergo additional treatment visit 52 week .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Give signed write informed consent participate 2 . At least 40 year age old 80 year age 3 . COPD patient symptomatic 4 . Must receive one inhaled bronchodilator maintenance therapy 5 . Must document history COPD exacerbations 1 . Current diagnosis asthma 2 . COPD due α1Antitrypsin Deficiency 3 . Known active tuberculosis , lung cancer , cystic fibrosis , significant bronchiectasis , Pulmonary resection Lung Volume Reduction Surgery past 6 month . 4 . Longtermoxygen therapy ( ≥ 15 hour day ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>COPD</keyword>
</DOC>